VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells.
The companies said they are discussing next steps in the collaboration, which VERAXA noted demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. This is a significant development as it expands the therapeutic scope of AOCs into immunology, potentially offering a new class of treatments for chronic conditions that affect millions worldwide.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The collaboration with Secarna combines VERAXA's conjugation technology with Secarna's expertise in antisense oligonucleotides, aiming to create targeted therapies that minimize off-target effects. The positive early results validate the concept that AOCs can enhance the potency of oligonucleotides by delivering them specifically to disease-associated cells, which could lead to more effective treatments with fewer side effects.
For investors, this news is important because it demonstrates VERAXA's ability to expand its platform beyond oncology, potentially opening up larger markets in autoimmune and chronic inflammatory diseases. The company's technology could become a versatile tool for targeted delivery of various therapeutic payloads, enhancing its pipeline and partnering opportunities.
For more information on VERAXA Biotech, visit the company's newsroom at http://ibn.fm/VRXA. To view the full press release, visit https://ibn.fm/IF9Cy.
